{"product_id":"mayo-clinic-heart-failure-review-online-program-2020-videos","title":"Mayo Clinic Heart Failure Review Online Program 2020 ( VIDEOS)","description":"\u003cdiv class=\"prod-edition\"\u003e\r\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\r\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\r\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-id=\"bbb44b8\" data-element_type=\"widget\" data-widget_type=\"heading.default\"\u003e\r\n\u003ch3 class=\"product-title product_title entry-title\"\u003eMayo Clinic Heart Failure Review Online Program 2020 ( VIDEOS)\u003c\/h3\u003e\r\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\r\n\u003cul\u003e\r\n \t\u003cli style=\"text-align: center;\"\u003e\r\n\u003ch4\u003eMayo Clinic Heart Failure Review will provide an overview of all aspects of heart failure and transplantation.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli style=\"text-align: center;\"\u003e\r\n\u003ch4\u003eExpert faculty will provide in-depth didactics on state-of-the-art subjects in heart failure with preserved and reduced ejection fraction, causes and management of patient with HF, management of comorbidities, and evaluation and management of patients with pulmonary arterial hypertension.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eIn addition, updates on the latest knowledge and advances in mechanical circulatory devices and heart transplantation are also integrated into the course for the practicing cardiologist wishing to review and update. The full spectrum of heart failure practice will be reviewed ranging from basic evaluation and management and device-based treatments. This includes topics reviewing advanced heart failure and cardiac transplant and immunosuppression.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eThis comprehensive online course will give you 365 days of access to a personalized and adaptive online learning curriculum that will save study time, most importantly enable you to integrate the most current medical knowledge into your daily practice, and give you confidence to pass the exam.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eCourse Learning Objectives\u003c\/h4\u003e\r\n\u003ch4\u003eUpon conclusion of this program, participants should be able to:\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eIdentify relevant features of national heart failure guidelines\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eDiscuss the clinical profile of heart failure and differentiate between reduced and preserved ejection fraction patients\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eDescribe how to utilize medical devices and surgical therapies in the care of heart failure patients\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003e Characterize the timing and expected outcome for surgical interventions in heart failure patients including those with ischemic heart disease and valvular heart disease\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eTarget Audience\u003c\/h4\u003e\r\n\u003ch4\u003eThis comprehensive online program is intended for cardiologists, cardiovascular fellows, internists, advance practice providers and others who commonly care for patients with heart failure.  Individuals preparing for the ABIM Advanced Heart Failure and Cardiac Transplantation certification\/recertification exam will find information and format valuable.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eTopics\/Speakers:\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003e\u003cu\u003eEvaluation of Heart Failure\u003c\/u\u003e\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eThe Epidemiology of Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eVeronique L. Roger, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eStage A and B Heart Failure, Risk Factor, and the Role of Prevention to Symptomatic HF\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eHorng H. Chen, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eClinical Assessment and Prognosis in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003ePaul M. Mckie, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBiomarkers in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eMargaret M. Redfield, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eExercise Testing and Physiology in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBarry A. Borlaug, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eNormal Cardiac Physiology\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBarry A. Borlaug, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eHemodynamics of Heart Failure with Reduced Ejection Fraction (HFrEF)\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBarry A. Borlaug, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eHemodynamics of Heart Failure with Preserved Ejection Fraction (HFpEF)\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBarry A. Borlaug, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eEvaluation of New Onset Heart Failure with Reduced Ejection Fraction\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003ePaul M. McKie, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eEvaluation of Heart Failure Preserved Ejection Fraction (HFpEF): Pathophysiology and Diagnosis\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eMargaret M. Redfield, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003e\u003cu\u003eSpecific Etiologies of Heart Failure\u003c\/u\u003e\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eCardiomyopathies\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eSteve R. Ommen, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eCardiac Amyloid\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eMartha Grogan, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eConstrictive Pericarditis\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eJae K. Oh, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eAdult Congenital Heart Disease: What the Heart Failure Specialist Needs to Know\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eAlexander C. Egbe, M.B.B.S., M.P.H.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003ePeripartum Cardiomyopathy\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eSabrina D. Phillips, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eStress Induced Cardiomyopathy\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eAbhiram Prasad, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eMyocarditis and Sarcoid: Evaluation and Management\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eLeslie T. Cooper, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eCardio-Oncology: What the Heart Failure Specialist Needs to Know\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eJoerg Herrmann, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eNonischemic Dilated Cardiomyopathy: Evolving Genetics\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eRichard J. Rodeheffer, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003e\u003cu\u003eImaging in Heart Failure\u003c\/u\u003e\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eEchocardiography in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBarry L. Karon, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003ePathologic Atlas of Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBrooks S. Edwards, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eMRI and CT Imaging in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eNandan S. Anavekar, M.B., B.Ch.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eNuclear Imaging in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eOmar F. Abou Ezzeddine, M.D., C.M., M.S.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003e\u003cu\u003eTreatment of Heart Failure\u003c\/u\u003e\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eDecompensated Heart Failure: Pathophysiology and Treatment\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBarry L. Karon, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eChronic Drug Therapy for Heart Failure Reduced Ejection Fraction (HFrEF) I\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eGrace Lin, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eChronic Drug Therapy for Heart Failure Reduced Ejection Fraction (HFrEF) II\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eGrace Lin, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eImplantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT) in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eSamuel J. Asirvatham, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eTreatment of Garden Variety HFpEF and Identification of Common Masqueradors\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBarry A. Borlaug, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eCritical Care in HF and Cardiogenic Shock\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eJacob C. Jentzer, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eRemote Monitoring in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eMargaret M. Redfield, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003e\u003cu\u003eComorbidities of Heart Failure\u003c\/u\u003e\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eSleep Disordered Breathing in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eVirend Somers, M.D., Ph.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eDiabetes in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eVinaya Simha, M.B.B.S.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eObesity in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBarry A. Borlaug, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eCoronary Disease and Revascularization in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBernard J. Gersh, M.B., Ch.B., D.Phil.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eCardiorenal Syndrome\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eJohn C.Burnett, Jr., M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eAtrial Arrhythmias in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eDouglas L. Packer, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eVentricular Arrhythmias, Intracardiac Electrograms and Implantable Monitors in Heart Failure\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eAbhishek J. Deshmukh, M.B.B.S.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eValve Disease in Heart Failure: What the HF Specialist Needs to Know\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eMackram F. Eleid, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003e\u003cu\u003eMechanical Circulatory Support\u003c\/u\u003e\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003ePatient Selection and Evaluation for Ventricular Assist Device\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eRichard J. Rodeheffer, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003ePostoperative Management of Mechanical Circulatory Device and Transplant\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eAndrew L. Rosenbaum, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eTemporary Mechanical Circulatory Support and ECMO: Devices, Complications, and Management\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eJohn M. Stulak, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eDurable Ventricular Assist Devices\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eAndrew L. Rosenbaum, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eMechanical Circulatory Support: Intra-Operative Complications and Post Implant Management\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eJohn M. Stulak, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003e\u003cu\u003eHeart Transplantation\u003c\/u\u003e\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eThe Patient with Advanced Heart Failure: Left Ventricular Assist Device vs. Transplant\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eAlfredo L. Clavell, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eTransplant: Patient Selection, Listing Criteria, and Evaluation\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBarry A. Boilson, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eRejection Surveillance\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eBrooks S. Edwards, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eTransplant Immunology\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eMark D. Stegall, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eImmunosuppressive Therapy and Post Transplant Considerations\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eSudhir S. Kushwaha, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003ePalliative Care\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eF. Andrew Bock, D.O.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003e\u003cu\u003ePulmonary Hypertension\u003c\/u\u003e\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003ePulmonary Arterial Hypertension: Essential Knowledge\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eRobert P. Frantz, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003ePulmonary Hypertension: Systematic and Efficient Evaluation\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eRobert P. Frantz, M.D.\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eDate of Original Release: September 21, 2020\u003c\/h4\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954558111842,"sku":"MED-AMB06049","price":45.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Mayo-Clinic-Heart-Failure-Review-Online-Program-2020-CME-VIDEOS.jpg?v=1779379676","url":"https:\/\/meducourse.com\/products\/mayo-clinic-heart-failure-review-online-program-2020-videos","provider":"Meducourse","version":"1.0","type":"link"}